Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by HighTide Therapeutics Inc.
ERA 2026: HighTide Therapeutics Presents New Findings Supporting HTD1801's Renoprotective Potential in Oral Presentation
June 04, 2026
From
HighTide Therapeutics Inc.
Via
ACN Newswire
Tickers
HTTIF
Dialogue with HighTide Therapeutics' CMO Dr. Filip Surmont: Moving Beyond the "Blockbuster" Legacy to Reshape Kidney Disease Treatment Through a Dual-Mechanism Approach
April 01, 2026
From
HighTide Therapeutics Inc.
Via
ACN Newswire
Tickers
HTTIF
HTD1801, a First-in-Class Anti-inflammatory Metabolic Modulator, Demonstrates Durable 52-Week Efficacy and Safety in Two Phase III Trials in Type 2 Diabetes Mellitus
October 30, 2025
From
HighTide Therapeutics Inc.
Via
ACN Newswire
Tickers
HTTIF
EASD 2025 | HighTide Therapeutics Announces Oral Presentation of Phase 3 Data in Patients with Type 2 Diabetes
September 16, 2025
From
HighTide Therapeutics Inc.
Via
ACN Newswire
Tickers
HTTIF
HighTide Therapeutics to Showcase New Analyses of Phase 2 MASH/T2DM Studies of Berberine Ursodeoxycholate (HTD1801) and Pre-Clinical Results of Rimtoregtide (HTD4010) in Presentations at EASL Congress 2025
April 24, 2025
From
HighTide Therapeutics Inc.
Via
ACN Newswire
HighTide Therapeutics Announces Publication of Phase 2 Study of Berberine Ursodeoxycholate for the Treatment of Type 2 Diabetes Mellitus in JAMA Network Open
March 03, 2025
From
HighTide Therapeutics Inc.
Via
ACN Newswire
EASD 2024 | HighTide Therapeutics Presents Oral Reports of Phase 2 Studies
September 10, 2024
From
HighTide Therapeutics Inc.
Via
ACN Newswire
HighTide Therapeutics Announces First Patient Dosed in Phase 2b Clinical Study Evaluating HTD1801 in NASH (the CENTRICITY study)
January 11, 2023
From
HighTide Therapeutics Inc.
Via
ACN Newswire
HighTide Therapeutics Raises $107 Million in Series C/C+ Financing to Advance Innovative Pipeline and Business Collaborations
January 05, 2023
From
HighTide Therapeutics Inc.
Via
ACN Newswire
Berberine Ursodeoxycholate (HTD1801) Consistently Demonstrates Comprehensive Benefits for Patients with Type 2 Diabetes Mellitus, Approaching NDA
April 14, 2025
From
HighTide Therapeutics Inc.
Via
ACN Newswire
HighTide Therapeutics Presents Analyses of a Phase 2 T2DM Study at the ADA Scientific Sessions, Highlighting Glycemic and Cardiometabolic Benefits of Berberine Ursodeoxycholate (HTD1801)
June 21, 2024
From
HighTide Therapeutics Inc.
Via
ACN Newswire
HighTide Therapeutics Presents Analyses of Phase 2a MASH Study at the 2024 International Liver Congress, Reinforcing and Further Characterizing the Efficacy and Safety of Berberine Ursodeoxcyholate (HTD1801)
June 04, 2024
From
HighTide Therapeutics Inc.
Via
ACN Newswire
HighTide Therapeutics Appoints Jin Chen, Ph.D., as SVP DMPK and Clinical Pharmacology
January 06, 2022
From
HighTide Therapeutics Inc.
Via
Business Wire
HighTide Therapeutics to Present New PSC and NASH Clinical Data at AASLD 2021
October 28, 2021
From
HighTide Therapeutics Inc.
Via
Business Wire
HighTide Therapeutics’ HTD1801 Demonstrates Reduced Liver Fat, Improved Glycemic Control and Other Health Measures in Diabetic NASH Patients
September 21, 2021
From
HighTide Therapeutics Inc.
Via
Business Wire
HighTide Therapeutics Announces the Presentation of Topline Results of Phase 2 Study of HTD1801 in PSC Patients at the International Liver Congress 2021
June 21, 2021
From
HighTide Therapeutics Inc.
Via
Business Wire
HighTide Announces NMPA Approval for HTD1801 Clinical Trial in China
May 27, 2021
From
HighTide Therapeutics Inc.
Via
Business Wire
HighTide to Present at the BofA Securities 2021 Health Care Conference
April 28, 2021
From
HighTide Therapeutics Inc.
Via
Business Wire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
